The drugs are expected to enter the national health insurance system

Recently, the National Health Insurance Administration issued the 2020 National Health Insurance Drug Catalog Adjustment Work Programme.
Compared to the adjustment plan announced in 2019, the 2020 consultation edition will be included in the list of new drugs that are urgently needed abroad, encourage generic drugs, or encourage research and development to declare the list of children's drugs, and approved by the State Drug Administration before August 17, 2020.
In terms of this adjustment plan, the National Health Insurance Administration has focused on clinical necessity, centralized procurement, innovative medicines and local medicines, of which pharmacoeconomics has become the main measure, and drugs that perform poorly or have serious side effects have been largely excluded.
that is, the standard adjustment will speed up the withdrawal of clinically ineffective drugs, and clinically urgently needed, drug-based principles of new drugs will also get access to health insurance tickets, to achieve rapid release.
Now, the dynamic adjustment mechanism of the medical insurance catalogue is initially established, and drugs with significant clinical value will enter the medical insurance catalogue more and more quickly, so as to realize the whole idea of the health insurance bureau changing the cage for birds and optimizing the payment structure.
in this context and trend, which drugs have a better chance of getting health care? For example, a few days ago, the first treatment of adult moderate-severe specialty dermatitis targeted biological agent Dabito ® (Du Puliu monoanti) in the domestic market.
It is known that moderate to severe endexual dermatitis (atopic dermatitis, AD) is a refroutable systemic immune disease, with recurrent violent itching and rash as the main clinical manifestations, patients often combined with allergic rhinitis, asthma and other type 2 inflammatory diseases.
, the lack of safe, effective and long-term treatment is a challenge for these patients.
it is understood that the current treatment of specific dermatitis is based on the patient's condition to develop external medications - such as topical topical glucoticoids, oral glucoticoids and immunosuppressants.
, however, oral glucoticoids and immunosuppressants, long-term medication may have side effects, i.e. clinically there is still a lack of effective and safe means.
To some extent, the listing of Dopriyu monoantigen has broken this gap in the market - it is the world's first and only approved treatment for severe endemic dermatitis in adults targeted biological agents, the effectiveness and safety has been confirmed by a number of clinical studies and real-world studies.
In addition to dupreyu monoantigen, research institutions have compiled a list of drugs that are in line with the adjustment program, with several innovative monoclonal antibody drugs listed worldwide, such as Iloyu monoanti, Daremu monoanti and Pabloju monoanti.
"New Drugs" is the highlight of the newly released adjustment program of the National Health Insurance Administration, there are a number of drugs eligible, can be included in the selection of the health insurance catalog, among them, innovative drugs may have greater access to health insurance, the biggest bright spot of the program is to include more innovative drugs, including domestic innovative drugs, imported innovative drugs, the proposed addition of 7 categories of drugs, Articles 3, 5, 7 are targeted at new drugs.
when it comes to innovative drugs, the closest link to them is the health care negotiations.
The specific situation of several negotiations on access can infer the future trend of innovative drugs: the number of times and several times the expansion of the list of drugs negotiated for access, promoting more innovative drugs into the health insurance catalog, expanding market space for innovative drugs, and ensuring that health insurance is implemented into rigid drugs.
but not all innovative drugs can be accessed, and only medicines that meet the principle of "clinical needs of medicines, fund affordability" will be given priority in the health insurance directory.
, the NSA is still based on the clinical needs of innovative drugs and pharmacoeconomic considerations, and ultimately decide whether to include innovative drugs in medicare payments - cost-effective innovative drugs, in order to enter health insurance.
american economics results show that, compared with the best support therapy, the treatment of moderate to severe idiopathic dermatitis in adults has a cost-effective advantage and can reduce the cost of treating other systemic immunological diseases.
The urgent need is the first consideration it is worth noting that the medical insurance negotiations are based on clinically superior varieties, life-saving anti-cancer drugs, children's drugs, innovative drugs and other major diseases treatment drugs, simply put - patients urgently need to greatly improve the quality of life of patients and their families, the efficacy of clear, clinically necessary new drugs, good drugs, will enter the fast lane of medical insurance drug catalog adjustment.
August 5, the China Association for Health Promotion and Education, in cooperation with Sanofi China, released the first "China Special Dermatitis Patient Survival Research Report."
After nearly half a year of research and data collation, the report for the first time focused on the group of patients with moderate to severe specific dermatitis, showing the true survival of patients with specific dermatitis in China: more than 75% of doctors are not satisfied with the existing treatment plan; Itching symptoms are an urgent need of 75.8% of moderate to severe patients, the incidence of patients is young, the course of the disease averages nearly 10 years, the overall affected skin loss area of more than 30%, more than 10% of patients have suicidal tendencies, 71.2% of patients have experienced discrimination.
Overall, topical external hormone and emollient care is the doctor's main treatment plan, some patients with severe need to use systematic oral drugs, doctors and patients on the existing treatment plan satisfaction is low, mainly reflected in the existing treatment effect and adverse reactions.
treatment of itching symptoms and repair of dermatation is the most urgent treatment needs of patients with moderate to severe dermatitis, patients are eager to use drugs with fewer side effects.
this side reflects the clinical need for dopliu monoants.
For patients with moderate to severe endexual dermatitis, more than 80% of adult patients are 18-55 years of age, the backbone of society, this part of the patients with good treatment can be returned to society, become a pillar of productivity.
In the future, access to health care will become normal, such as the high clinical value of such new drugs, the health insurance cycle will be greatly shortened to achieve rapid release, which also gives patients more room to choose drugs, and further improve the quality of life of patients."